Search Results - Birgitta Lauri

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
    Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group

    Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A st... by Maria Winqvist, Anna Asklid, PO Andersson, Karin Karlsson, Claes Karlsson, Birgitta Lauri, Jeanette Lundin, Mattias Mattsson, Stefan Norin, Anna Sandstedt, Lotta Hansson, Anders Österborg

    Published 2016-12-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort

    Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort by Maria Winqvist, Per-Ola Andersson, Anna Asklid, Karin Karlsson, Claes Karlsson, Birgitta Lauri, Jeanette Lundin, Mattias Mattsson, Stefan Norin, Anna Sandstedt, Richard Rosenquist, Florentin Späth, Lotta Hansson, Anders Österborg, for the Swedish CLL Group

    Published 2019-05-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study

    Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study by Göran Wålinder, Anna Genell, Gunnar Juliusson, Ronald Svensson, Antonio Izarra Santamaria, Jacob Crafoord, Kristina Carlson, Dorota Knut‐Bojanowska, Ljupco Veskovski, Birgitta Lauri, Johan Lund, Ingemar Turesson, Markus Hansson, Cecilie Hveding Blimark, Hareth Nahi

    Published 2022-11-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013

    First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013 by Sandra Eketorp Sylvan, Anna Asklid, Hemming Johansson, Jenny Klintman, Jenny Bjellvi, Staffan Tolvgård, Eva Kimby, Stefan Norin, Per-Ola Andersson, Claes Karlsson, Karin Karlsson, Birgitta Lauri, Mattias Mattsson, Anna Bergendahl Sandstedt, Maria Strandberg, Anders Österborg, Lotta Hansson

    Published 2019-04-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS

    P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MY... by Raija Silvennoinen, Anu Partanen, Anders Waage, Valdas Pečeliūnas, Fredrik Schjesvold, Pekka Anttila, Katarina Uttervall, Marjaana Säily, Mervi Putkonen, Kristina Carlson, Einar Haukas, Marja Sankelo, Damian Szatkowski, Markus Hansson, Anu Marttila, Per Axelsson, Ronald Svensson, Birgitta Lauri, Maija Mikkola, Conny Karlsson, Johanna Abelsson, Erik Ahlstrand, Anu Sikiö, Monika Klimkowska, Reda Matuzeviciene, Mona Hoyseter Fenstad, Sorella Ilveskero, Hareth Nahi

    Published 2023-08-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

    Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial by Alexander Schmitz, Rasmus Froberg Brøndum, Hans Erik Johnsen, Ulf-Henrik Mellqvist, Anders Waage, Peter Gimsing, Davine Hofste op Bruinink, Vincent van der Velden, Bronno van der Holt, Markus Hansson, Niels Frost Andersen, Ulf Christian Frølund, Carsten Helleberg, Fredrik H. Schjesvold, Lucia Ahlberg, Nina Gulbrandsen, Bjorn Andreasson, Birgitta Lauri, Einar Haukas, Julie Støve Bødker, Anne Stidsholt Roug, Martin Bøgsted, Marianne T. Severinsen, Henrik Gregersen, Niels Abildgaard, Pieter Sonneveld, Karen Dybkær

    Published 2022-02-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

    Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk by Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay Nooka, Hang Quach, Markus Munder, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Pieter Sonneveld, Tineke Casneuf, Nikki DeAngelis, Himal Amin, Jon Ukropec, Rachel Kobos, Maria-Victoria Mateos

    Published 2020-08-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

    Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR by Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay K. Nooka, Hang Quach, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Emma C. Scott, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Pieter Sonneveld, David Soong, Tineke Casneuf, Christopher Chiu, Himal Amin, Ming Qi, Piruntha Thiyagarajah, A. Kate Sasser, Jordan M. Schecter, Maria-Victoria Mateos

    Published 2018-12-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: